This new plain language summary from Future Oncology can help people understand if the treatment afatinib could be an option for people who have already been treated for metastatic squamous cell carcinoma of the lung with pembrolizumab plus chemotherapy.
Read the full article here.
The original article on which this summary is based is called ‘Second-line afatinib or chemotherapy following immunochemotherapy for the treatment of metastatic, squamous cell carcinoma of the lung: real-world effectiveness and safety from a multisite retrospective chart review in the USA’ and was originally published in the journal Clinical Lung Cancer. The original article can be read here.